Coeptis Therapeutics Advances Cell Therapy Pipeline While Pursuing Strategic Merger with Cryptocurrency Mining Company
Key Insights
Coeptis Therapeutics, a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, has received shareholder approval for its merger with cryptocurrency mining company Z Squared Inc (search).
The company's therapeutic portfolio includes DVX201, a clinical-stage natural killer cell therapy, and SNAP-CAR (search) universal multi-antigen CAR technology licensed from the University of Pittsburgh.
Nasdaq has approved the listing application for the post-merger entity, which will trade under ticker symbol "ZSQR" and is expected to close in Q2 2026.
Coeptis Therapeutics Holdings (search), Inc. (Nasdaq: COEP) has secured key regulatory and shareholder approvals for its proposed merger with Z Squared Inc (search)., a digital infrastructure company focused on cryptocurrency mining operations. The transaction represents an unusual combination of biopharmaceutical innovation and digital asset mining, with the merged entity expected to trade on Nasdaq under the ticker symbol "ZSQR."
Cell Therapy Platform Development
Coeptis operates as a biopharmaceutical and technology company through its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc. The company focuses on developing innovative cell therapy platforms targeting cancer, autoimmune, and infectious diseases with the goal of advancing treatment paradigms and improving patient outcomes.
The company's therapeutic portfolio centers on assets licensed from Deverra Therapeutics (search), including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing SNAP-CAR (search), a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, alongside GEAR cell therapy and companion diagnostic platforms developed in collaboration with VyGen-Bio (search) and medical researchers at the Karolinska Institute (search).
Technology Division Expansion
Building on its core biopharmaceutical competencies, Coeptis has established a Technology Division focused on enhancing operational capabilities through advanced technologies. This division incorporates AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group (search), designed to optimize business processes and improve overall efficiency.
Merger Progress and Timeline
Coeptis shareholders approved the merger proposal on January 30, 2026, clearing a key closing condition for the transaction. Nasdaq subsequently approved the listing application for the post-merger company's common stock on the Nasdaq Global Market, subject to customary conditions and the closing of the proposed merger.
Upon completion of the merger, Z Squared will become a wholly owned subsidiary of Coeptis, and the company will change its corporate name to Z Squared Inc (search). The transaction remains subject to satisfaction of remaining customary closing conditions and is expected to close in Q2 2026.
Strategic Rationale
The merger combines Coeptis's biopharmaceutical operations with Z Squared's digital infrastructure business, which focuses on securing the Dogecoin and Litecoin networks through institutional-scale mining operations. Z Squared is expected to deploy 9,800 ASIC miners across facilities in North Carolina, South Carolina, and Iowa, positioning the merged entity as the largest publicly-traded pure-play Dogecoin miner in the United States.
Z Squared's operational model emphasizes efficiency, discipline, and risk management, with mined assets typically converted to USD or stablecoins within 24 hours, aligning with a cash-flow-focused strategy rather than speculative holding.
Regulatory Compliance
Headquartered in Wexford, Pennsylvania, Coeptis operates within the regulatory framework established by the FDA, ensuring all activities align with the highest standards of compliance and patient care. The company has filed the necessary registration statements and proxy materials with the Securities and Exchange Commission in connection with the proposed merger.